Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) has shared an update.
HUTCHMED (China) Limited has announced the renewal of its contract with the China National Healthcare Security Administration, ensuring continued inclusion of its drugs ELUNATE®, ORPATHYS®, and SULANDA® in the National Reimbursement Drug List (NRDL) effective January 2023. Additionally, TAZVERIK® has been added to the first edition of the National Commercial Health Insurance Innovative Drug List, which is part of China’s multi-level medical insurance system. This development enhances patient access to innovative treatments and supports the sustainable growth of China’s pharmaceutical sector.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved globally, including in the US, Europe, and Japan.
YTD Price Performance: -2.44%
Average Trading Volume: 6,305,522
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$19.19B
For detailed information about 0013 stock, go to TipRanks’ Stock Analysis page.